anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a means for assaying buckwheat allergen, a means for assaying the primary cause of buckwheat allergen crisis in an individual and a means for treating buckwheat allergen.  <P>SOLUTION: The polypeptide comprises the epitope sequence of buckwheat allergen protein having a specific amino sequence. The function-deleted type mutation polypeptide thereof is obtained. The desensitization therapeutic agent against buckwheat allergen comprises a denatured polypeptide obtained by denaturing the polypeptide or the function-deleted type mutation peptide desensitization therapeutic. The method for assaying allergen in buckwheat comprises assaying the epitope sequence. The antibody against the polypeptide is obtained. The nucleic acid encoding the polypeptide is obtained. The kit for assaying the epitope sequence contains the antibody or the nucleic acid. The kit for assaying the primary cause of buckwheat allergen crisis in an individual to be examined contains the peptide.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Devices and processes (e.g., improved Plasticized Melt Flow processes (PMF) or improved Phase Separation Polymer Concentration (PSPC), etc.) used to make resorbable and non-resorbable structures for treating and/or healing of tissue defects are disclosed. Among the advantages of using these improved processes are the preservation of molecular weight and the broadening of the processing conditions for temperature sensitive polymers and therapies This reduction in processing temperature, pressure and time can help to preserve the molecular weight and/or integrity of the final product or any additive incorporated therein. The present invention relates to an improved porous implant wherein the pores of the implant present a second modeling material on their surfaces. This second material provides a textured or roughened face to the internal surfaces of pores. Additionally, this second material can be incorporated in sufficient quantity to, among other things, create a microporous network connecting interior closed cell pores with the exterior of the device.
If there are no unexpected toxicities (no more than 3 of 12 patients with grade 3+ treatment related events as defined in 4.1.1), an additional 28 patients will be enrolled. Unlike the first 12 patients, these additional 28 patients will initiate both CDX-1401 and MPDL3280A on the same day, and will undergo tumor biopsies before starting trial therapy and after their 3rd CDX-1401 vaccination (during week 6).
BACKGROUND: Acute hypoxic proximal tubule (PT) injury and subsequent maladaptive repair present high mortality and increased risk of acute kidney injury (AKI) - chronic kidney disease (CKD) transition. Human bone marrow mesenchymal stem cell-derived exosomes (hBMMSC-Exos) as potential cell therapeutics can be translated into clinics if drawbacks on safety and efficacy are clarified. Here, we determined the real-time effective dose and treatment window of allogeneic hBMMSC-Exos, evaluated their performance on the structural and functional integrity of 3D microfluidic acute hypoxic PT injury platform.
METHODS: hBMMSC-Exos were isolated and characterized. Real-time impedance-based cell proliferation analysis (RTCA) determined the effective dose and treatment window for acute hypoxic PT injury. A 2-lane 3D gravity-driven microfluidic platform was set to mimic PT in vitro. ZO-1, acetylated α-tubulin immunolabelling, and permeability index assessed structural; cell proliferation by WST-1 measured functional integrity of PT.
RESULTS: hBMMSC-Exos induced PT proliferation with ED50 of 172,582 µg/ml at the 26th hour. Hypoxia significantly decreased ZO-1, increased permeability index, and decreased cell proliferation rate on 24-48 h in the microfluidic platform. hBMMSC-Exos reinforced polarity by a 1.72-fold increase in ZO-1, restored permeability by 20/45-fold against 20/155 kDa dextran and increased epithelial proliferation 3-fold compared to control.
CONCLUSIONS: The real-time potency assay and 3D gravity-driven microfluidic acute hypoxic PT injury platform precisely demonstrated the therapeutic performance window of allogeneic hBMMSC-Exos on ischemic AKI based on structural and functional cellular data. The novel standardized, non-invasive two-step system validates the cell-based personalized theragnostic tool in a real-time physiological microenvironment prior to safe and efficient clinical usage in nephrology.
In In the prodn. by extn. of the rhizomes of Curcuma longa or C. xanthorrhiza, the dried comminuted rhizomes are extracted with 1-3C alcohols; the alcoholic extract is concd., treated with water and extracted with 5-7C aliphatic hydrocarbons; and the solvent is evapd. from each of the two resulting liq. phases to give curcuma essential oil (hydrocarbon phase) and curcuma dry extract (aq. alcoholic phase). The dry extract and the ethereal oil both have a biliary effect. The process is simple. The dry extract has high curcumin content (up to 54% for Curcuma longa or 26% for C. xanthorrhiza).
OBJECTIVES: Left atrial appendage occlusion during cardiac surgery is a therapeutic option for stroke prevention in patients with atrial fibrillation. The effectiveness and safety of left atrial appendage occlusion have been evaluated in several studies, including the LAAOS-III trial. While these studies have demonstrated efficacy and safety, the long-term economic impact of this surgical technique has not yet been assessed. Here, we aimed to evaluate the cost-effectiveness and cost-utility of left atrial appendage occlusion during cardiac surgery over a long-term time horizon.
METHODS: Our study was based on a model representing an hypothetical cohort with the same characteristics as LAAOS-III trial patients. We modelled the incidence of ischemic strokes and systemic embolisms in each intervention arm: "occlusion" and "no-occlusion," using a one-month cycle length with a 20-year time horizon. Regarding occlusion devices, sutures, staples, or an approved surgical occlusion device (AtriClip™-AtriCure, Ohio, USA) could be used.
RESULTS: Our model generated an average cost savings of 607 euros per patient and an incremental gain of 0.062 quality-adjusted life years (QALYs), resulting an incremental cost-utility ratio (ICUR) of €-9,775/QALY. The scenario analysis in which occlusion was systematically performed using the AtriClip™ device generated an ICUR of €3,952/QALY gained.
CONCLUSIONS: In the base-case analysis, the strategy proved to be more effective and less costly, confirming left atrial appendage occlusion during cardiac surgery as an economically dominant strategy. The scenario analysis also appeared cost-effective, although it did not result in cost savings. This study provides a new perspective on the assessment of the cost-effectiveness of these techniques.
Paroxetine tablets should be administered as a single daily dose with or without food, usually in the morning. The recommended initial dose is 20 mg/day. Patients were dosed in a range of 20 to 50 mg/day in the clinical trials demonstrating the effectiveness of paroxetine tablets in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 20 mg dose may benefit from dose increases, in 10 mg/day increments, up to a maximum of 50 mg/day. Dose changes should occur at intervals of at least one week.
BACKGROUND: Ischemic stroke (IS) ranks as the second common cause of death worldwide. However, a narrow thrombolysis timeframe and ischemia-reperfusion (I/R) injury limits patient recovery. Moreover, anticoagulation and antithrombotic drugs do not meet the clinical requirements. Studies have demonstrated close communication between the brain and gut microbiota in IS. Notoginsenoside R1 (NG-R1), a significant component of the total saponins from Panax notoginseng, has been demonstrated to be effective against cerebral I/R injury. Total saponins have been used to treat IS in Chinese pharmacopoeia. Furthermore, previous research has indicated that the absorption of NG-R1 was controlled by gut microbiota.
STUDY DESIGN: This study aimed to access the impact of NG-R1 treatment on neuroinflammation and investigate the microbiota-related mechanisms.
RESULTS: NG-R1 significantly reduced neuronal death and neuroinflammation in middle cerebral artery occlusion/reperfusion (MCAO/R) models. 16S rRNA sequencing revealed that NG-R1 treatment displayed the reversal of microbiota related with MCAO/R models. Additionally, NG-R1 administration attenuated intestinal inflammation, gut barrier destruction, and systemic inflammation. Furthermore, microbiota transplantation from NG-R1 exhibited a similar effect in the MCAO/R models.
CONCLUSION: In summary, NG-R1 treatment resulted in the restoration of the structure of the blood-brain barrier (BBB) and reduction in neuroinflammation via suppressing the stimulation of astrocytes and microglia in the cerebral ischemic area. Mechanistic research demonstrated that NG-R1 treatment suppressed the toll-like receptor 4/myeloid differentiation primary response 88/nuclear factor kappa B (TLR4/MyD88/NF-κB) signaling pathway in both the ischemic brain and colon. NG-R1 treatment enhanced microbiota dysbiosis by inhibiting the TLR4 signaling pathway to protect MCAO/R models. These findings elucidate the mechanisms by which NG-R1 improve stroke outcomes and provide some basis for Panax notoginseng saponins in clinical treatment.
Syntheses of polyethyleneglycol (PEG)-lipid conjugates are disclosed. Such syntheses involve stepwise addition of small PEG oligomers to a glycerol backbone until the desired chain size is attained. Polymers resulting from the syntheses are highly monodisperse. The present invention provides several advantages such as simplified synthesis, high product yield and low cost for starting materials. The present synthesis method is suitable for preparing a wide range of conjugates. In another aspect, the invention comprises PEG lipid conjugates having a glycerol backbone covalently attached to one or two monodisperse PEG chains and one or two lipids. These conjugates are especially useful for pharmaceutical formulations.
Objective: To investigate the effect of tocilizumab (TCZ) on ventricular arrhythmias (VAs) after myocardial infarction (MI) in Sprague-Dawley rats and explore its potential mechanism. Methods: The random number table method was used to divide 32 adult male Sprague-Dawley rats into 4 groups: Sham group, TCZ group, MI group and MI+TCZ group, with 8 rats in each group. The MI model was established by ligation of the left anterior descending branch of the coronary artery in the MI and MI+TCZ groups, and only sutured without ligation in the Sham and TCZ groups. TCZ was injected into the left superior cervical ganglion (SCG) of rats in the TCZ and MI+TCZ groups after successful modeling or sham operation, and the same amount of normal saline was injected in the Sham and MI groups. 24 h after successful modeling, ECG of rats in each group was recorded, heart rate variability (HRV, including low frequency power (LF), high frequency power (HF), LF/HF ratio), QT interval, QTc interval were calculated, and left ventricular effective refractory period (ERP) and VA inducibility were measured. Myocardial infarct size and tissue changes were observed with triphenyl tetrazolium chloride staining and HE staining. Real-time PCR analysis was used to detect the messager RNA (mRNA) expression of interleukin-6 (IL-6) and signal transducer and activator of transcription (STAT) 3 in SCG and potassium voltage-gated channel subfamily D member 2 (Kcnd2) in myocardial infarction periphery. The expression of c-fos in SCG was detected by immunofluorescence staining. Results: Compared with Sham group and MI+TCZ group, rats in MI group had higher LF and LF/HF ratio, longer QT interval and QTc interval, more VAs induced, lower HF and shorter ERP (P all<0.05). Triphenyl tetrazolium chloride staining and HE staining showed that rats in the Sham and TCZ groups had normal myocardial tissue structure, those in the MI group had severe myocardial injury, and those in the MI+TCZ group had less myocardial injury than those in the MI group. Real-ime PCR analysis showed that compared with Sham group and MI+TCZ group, mRNA expression levels of IL-6 and STAT3 in SCG of rats in MI group were higher, and mRNA expression level of myocardial Kcnd2 was lower (P all<0.05). Immunofluorescence staining showed that the content of c-fos in SCG of rats in MI group was higher than that of Sham group and MI+TCZ group (P all<0.05). Conclusions: TCZ may reduce neural activity of the SCG after MI by inhibiting the IL-6/STAT3 signaling pathway, thereby alleviating myocardial injury and inhibiting VAs.
The invention discloses a recombinant humanized III type collagen which is near-natural extracted collagen, which is recombinant humanized III type collagen of the following a) or b): a) The amino acid sequence is the recombinant humanized III type collagen of SEQ ID No. 1; b) The protein with recombinant humanized III type collagen activity is obtained by substituting and/or deleting and/or adding one or more amino acid residues in the amino acid sequence shown in SEQ ID No. 1. The invention obtains optimized genes from III type human collagen sequences through screening and transformation, constructs the optimized genes into Pichia pastoris secretion expression plasmids through homologous recombination, and obtains recombinant Pichia pastoris engineering strains with high-expression humanized III type collagen through electric transfer screening. And (3) fermenting, culturing and purifying after optimization to finally obtain the high-purity recombinant humanized III-type collagen. The recombinant humanized III type collagen is closer to natural extracted collagen in the high-level structure, and has potential application prospects in the fields of biomedical materials, cosmetics and the like.
The invention discloses cleansing cream with high-efficiency sterilization, and belongs to the field of hygiene products. The invention aims to provide a bactericidal cleansing cream product which is high-efficient and safe and is processed by adopting modern biotechnology. A formula of the cleansing cream mainly comprises a surfactant, a humectant, a nutritional agent, an emollient, essence, anda bactericide. The invention realizes that the cleansing cream removes dirt on skin, and also has good sterilization and disinfection functions. The cleansing cream utilizes a fermentation raw material with low cost, adopts the modern biotechnology, and has simple process and low cost. Thus the invention becomes the cleansing cream with strong sterilizing power, safety, low cost, and high technology content. The bactericide which is added into the cleansing cream and is obtained by processing the pure natural fermentation raw material through the modern biotechnology has the function of antisepsis and the characteristics of safety and high efficiency. No preservative needs to be added into the cleansing cream.
BACKGROUND: Maternal near-miss (MNM) is defined by the World Health Organization (WHO) working group as a woman who nearly died but survived a life-threatening condition during pregnancy, childbirth, or within 42 days of termination of pregnancy due to getting quality of care or by chance. Despite the importance of the near-miss concept in enhancing quality of care and maternal health, evidence regarding the prevalence of MNM, its primary causes and its determinants in Africa is sparse; hence, this study aimed to address these gaps.
METHODS: A systematic review and meta-analysis of studies published up to October 31, 2023, was conducted. Electronic databases (PubMed/Medline, Scopus, Web of Science, and Directory of Open Access Journals), Google, and Google Scholar were used to search for relevant studies. Studies from any African country that reported the magnitude and/or determinants of MNM using WHO criteria were included. The data were extracted using a Microsoft Excel 2013 spreadsheet and analysed by STATA version 16. Pooled estimates were performed using a random-effects model with the DerSimonian Laired method. The I2 test was used to analyze the heterogeneity of the included studies.
RESULTS: Sixty-five studies with 968,555 participants were included. The weighted pooled prevalence of MNM in Africa was 73.64/1000 live births (95% CI: 69.17, 78.11). A high prevalence was found in the Eastern and Western African regions: 114.81/1000 live births (95% CI: 104.94, 123.59) and 78.34/1000 live births (95% CI: 67.23, 89.46), respectively. Severe postpartum hemorrhage and severe hypertension were the leading causes of MNM, accounting for 36.15% (95% CI: 31.32, 40.99) and 27.2% (95% CI: 23.95, 31.09), respectively. Being a rural resident, having a low monthly income, long distance to a health facility, not attending formal education, not receiving ANC, experiencing delays in health service, having a previous history of caesarean section, and having pre-existing medical conditions were found to increase the risk of MNM.
CONCLUSION: The pooled prevalence of MNM was high in Africa, especially in the eastern and western regions. There were significant variations in the prevalence of MNM across regions and study periods. Strengthening universal access to education and maternal health services, working together to tackle all three delays through community education and awareness campaigns, improving access to transportation and road infrastructure, and improving the quality of care provided at service delivery points are key to reducing MNM, ultimately improving and ensuring maternal health equity.
Increasing numbers of very preterm infants are surviving and have chronic, complex healthcare needs due to prematurity. These infants experience increased healthcare utilization, long durations of stay in the Neonatal Intensive Care Unit (NICU), and are at high risk of developing prematurity-related complications. As a result, their care is complex, and families need structured training to effectively understand, monitor, and manage their infant's care. PREEMIE PROGRESS is an innovative, video-based intervention that applies evidence-based family management theories to better equip parents to meet the chronic, complex healthcare needs of their preterm infant. This research aims to 1) refine a novel family management program, called PREEMIE PROGRESS, through iterative usability and acceptability testing and 2) test feasibility and acceptability of the refined intervention and study procedures in a pilot randomized controlled trial. This project will use implementation science tools and approaches to refine the intervention and study procedures to ensure that PREEMIE PROGRESS addresses key program elements that will be important for future adoption and implementation in NICU settings. We anticipate that the intervention will decrease parent anxiety and depression, increase infant weight gain and receipt of mother's milk, and reduce neonatal healthcare utilization. The long-term goal of this project is to develop, test, and translate into NICU practice an efficacious family management intervention for parents of preterm infants. Dr. Weber will significantly advance nursing science through this project by obtaining preliminary feasibility and acceptability data for a scalable and sustainable intervention to facilitate family management and improve parent-infant health outcomes.
There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday and fasting is terminated at 0800 on Monday and Thursday.
Bendamustine, Bortezomib,and Dexamethasone for 8 cycles or 2 cycles beyond a confirmed complete response, assessed by IMWG criteria. Patients with stable disease and no intolerable toxicity may continue maintenance therapy with Bortezomib and Dexamethasone until disease progression or intolerable toxicity.
The safety of Sancuso was evaluated in a total of 404 patients undergoing chemotherapy who participated in two double-blind, comparator studies with patch treatment durations of up to 7 days. The control groups included a total of 406 patients who received a daily dose of 2 mg oral granisetron, for 1 to 5 days.

Adverse reactions considered by the investigators as drug-related occurred in 8.7% (35/404) of patients receiving Sancuso and 7.1% (29/406) of patients receiving oral granisetron. The most common adverse reaction was constipation that occurred in 5.4% of patients in the Sancuso group and 3.0% of patients in the oral granisetron group.

Table 1 lists the treatment emergent adverse reactions that occurred in at least 3% of patients treated with Sancuso or oral granisetron.

5-HT3 receptor antagonists, such as granisetron, may be associated with arrhythmias or ECG abnormalities. Three ECGs were performed on 588 randomized patients in the Phase 3 study: at baseline before treatment, the first day of chemotherapy, and 5 to 7 days after starting chemotherapy. QTcF prolongation greater than 450 milliseconds was seen in a total of 11 (1.9%) patients after receiving granisetron, 8 (2.7%) on oral granisetron and 3 (1.1%) on the patch. No new QTcF prolongation greater than 480 milliseconds was observed in any patient in this study. No arrhythmias were detected in this study.
The present invention relates to a pilose antler growth factor preparation and its production technology. It uses pilose antler as raw material and makes it pass through such processes of pulverization, digestion, suction-filtering, sterilization and chromatography etc. of filtration separation, etc. to obtain the invented polypeptide component preparation which mainly contains nerve growth factor, fibroblast growth factor and epithelial cell growth factor, etc. and has no foreign protein antigenicity. The invented product mainly is used for curing retrograde diseases of nerve system, brain trauma, anemia and diabetes. etc..
PROBLEM TO BE SOLVED: To provide an artificial denture backed with a silicone rubber on a surface of a body-attaching side of a dental plate. SOLUTION: Wax 3 is coated in a fixed thickness on the surface of the body-attaching side of dental plate 2 made from PMMA and artificial denture 1 is fixed with plaster 6 in lower flask 5 so that the wax 3 plane is exposed. When upper flask 4 and lower flask 5 are shut, plaster 6 is poured into the upper side of dental plate 2 including the wax 3 plane to be solidified by leaving. After flasks 4 and 5 are opened and wax 3 is washed out with a solvent and dental plate 2 is treated with dichloromethane and dried, an appropriate amount of silicone 8 added with a small amount of MMA is poured on dental plate 2. Flasks 4 and 5 are closed tightly to be moved into an autoclave and heated for 24 hours at about 50 deg.C at a pressure of about 3 atm. As a result, at the same time that the silicone rubber is polymerized, polymerization of MMA also proceeds in the vicinity of the surface.  This contributes to strong adhesion to dental plate 2 to give artificial denture 1 backed with soft silicone rubber 9.
PURPOSE:To collect salinomycin containing a new antibiotic in high yield, by cultivating a microorganism of the genus Streptomyces in a culture medium containing a fatty acid or a precursor therefor in producing the salinomycin by the fermentation method. CONSTITUTION:A microorganism, belonging to the genus Streptomyces, and having the ability to produce salinomycin, e.g. Streptomyces albus No. 80614 microorganism (FERM-P No. 419) is cultivated in a culture medium containing a fatty acid, e.g. inoleic acid, linolenic acid or oleic acid, or a fatty acid precursor, e.g. mono-, di- or triglyceride, as a main carbon source. Salinomycin is precipitated from the culture, and a solid part containing microbial cells is extracted to adsorb the salinomycin in an adsorbent. The adsorbed salinomycin is then eluted, purified and separated by the chromatography, etc. to afford the aimed salinomycin SY-1, SY-2 and new antibiotic SY-3-SY-8.